Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JZP3507 · 1 trial · 1 indication
ORR is the best response of confirmed complete response (CR), partial response (PR), or minor response (MR) during the study, as per RANO criteria
| Arm | Type | Description |
|---|---|---|
| JZP3507 (ONC206) | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| JZP3507 | DRUG | Participants will receive oral JZP3507 monotherapy twice daily, on 3 consecutive days per week in 28-day cycles. |
Key Inclusion Criteria: Age 1. Is ≥ 18 years of age at the time of signing the informed consent. Type of Participant and Disease Characteristics 2. Has histologically confirmed Grade 2 or 3 meningioma. 3. Has failed, is not a candidate for, or has declined standard of care treatment for mening...
JZP3507 is an investigational small molecule being studied for the treatment of recurrent Grade 2 or 3 meningioma. It is currently in Phase 2 clinical development for this oncology indication.
JZP3507 is being developed by Jazz Pharmaceuticals plc, a biopharmaceutical company traded on the NASDAQ under the ticker JAZZ.
JZP3507 is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 2 trial is currently recruiting participants.
JZP3507 is being evaluated in a Phase 2 clinical trial with the identifier NCT07533942, titled 'A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma'. The trial is recruiting 30 adult participants in the United States.
Yes, JZP3507 is also known as ONC206. The clinical trial NCT07533942 refers to the drug as JZP3507 (ONC206), indicating that both names refer to the same investigational compound.